In vitro models of long-term oestrogen deprivation utilise increased oestrogen receptor (ER) and are oestrogen hypersensitive, with emerging evidence that growth factor signalling contributes and interacts with ER. However, such models are commonly derived in the presence of serum growth factors that may force the resistance mechanism. Our new in vitro model, MCF-7X, has thus been developed under conditions of both oestrogen and growth factor depletion. ER expression, serine 118 phosphorylation on this receptor and its transcriptional activity were modestly increased compared to the parental MCF-7 cells, although MCF-7X cells were not oestrogen hypersensitive. Faslodex (0.1 μM) partially decreased ER and its transcriptional activity, with a...
Oestrogen receptor (ER) levels are usually maintained on acquisition of tamoxifen resistance in the ...
Although anti-endocrine therapies have significantly advanced the treatment of breast cancer, they p...
Background Tamoxifen still remains the most frequently used antioestrogen for the treatment of br...
In vitro models of long-term oestrogen deprivation utilise increased oestrogen receptor (ER) and are...
De novo insensitivity and acquired resistance to the selective oestrogen receptor modulator tamoxife...
Oestrogen deprivation strategies, notably aromatase inhibitors, are of increasing value in hormone s...
Growth of MCF7 McGrath human breast cancer cells (MCF7) under conditions of longterm oestrogen depri...
Cell culture models of antioestrogen resistance often involve applying selective pressures of oestro...
Abstract Background: MCF-7, T-47-D, ZR-75-1 human breast cancer cell lines are dependent on oestroge...
This paper describes the establishment of an antiestrogen-resistant MCF7 breast cancer cell subline ...
The progression of breast tumors to steroid-autonomous and antiestrogen-resistant phenotypes confoun...
Development of acquired resistance against antiestrogen treatment is a serious problem in human brea...
Human breast cancer cells (MCF-7, T-47-D and ZR-75-1) can adapt to circumvent any reduced growth rat...
Background: Efficacy of endocrine therapy is compromised when human breast cancer cells circumvent i...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
Oestrogen receptor (ER) levels are usually maintained on acquisition of tamoxifen resistance in the ...
Although anti-endocrine therapies have significantly advanced the treatment of breast cancer, they p...
Background Tamoxifen still remains the most frequently used antioestrogen for the treatment of br...
In vitro models of long-term oestrogen deprivation utilise increased oestrogen receptor (ER) and are...
De novo insensitivity and acquired resistance to the selective oestrogen receptor modulator tamoxife...
Oestrogen deprivation strategies, notably aromatase inhibitors, are of increasing value in hormone s...
Growth of MCF7 McGrath human breast cancer cells (MCF7) under conditions of longterm oestrogen depri...
Cell culture models of antioestrogen resistance often involve applying selective pressures of oestro...
Abstract Background: MCF-7, T-47-D, ZR-75-1 human breast cancer cell lines are dependent on oestroge...
This paper describes the establishment of an antiestrogen-resistant MCF7 breast cancer cell subline ...
The progression of breast tumors to steroid-autonomous and antiestrogen-resistant phenotypes confoun...
Development of acquired resistance against antiestrogen treatment is a serious problem in human brea...
Human breast cancer cells (MCF-7, T-47-D and ZR-75-1) can adapt to circumvent any reduced growth rat...
Background: Efficacy of endocrine therapy is compromised when human breast cancer cells circumvent i...
Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes...
Oestrogen receptor (ER) levels are usually maintained on acquisition of tamoxifen resistance in the ...
Although anti-endocrine therapies have significantly advanced the treatment of breast cancer, they p...
Background Tamoxifen still remains the most frequently used antioestrogen for the treatment of br...